Bank of New York Mellon
AARD

Bank of New York Mellon’s Aardvark Therapeutics AARD Stock Holding History

Bank of New York Mellon’s Portfolio AARD Stock Details AARD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-29,320
Closed -$111K – 4459
2026
Q1 		$111K Buy
29,320
+6,905
+31% +$71.6K ﹤0.01% 4090
2025
Q4 		$294K Buy
22,415
+6,892
+44% +$86K ﹤0.01% 3870
2025
Q3 		$206K Buy
+15,523
New +$175K ﹤0.01% 4007

Other funds holding AARD

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Citigroup
Citigroup New York $303B AUM 53.02% 1-Year Est. Return
Wealth Enhancement Advisory Services
Wealth Enhancement Advisory Services Plymouth, Minnesota $59.8B AUM 29.42% 1-Year Est. Return
Mercer Global Advisors
Mercer Global Advisors Denver, Colorado $80B AUM 26.12% 1-Year Est. Return
AHL
Abel Hall LLC Baton Rouge, Louisiana $579M AUM 54.21% 1-Year Est. Return
AAP
Arax Advisory Partners Denver, Colorado $15.1B AUM 27.93% 1-Year Est. Return
CUAMC
China Universal Asset Management Company Shanghai, China $1.67B AUM 89% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $4.08B AUM 58.77% 1-Year Est. Return
Russell Investments Group
Russell Investments Group London, United Kingdom $114B AUM 41.71% 1-Year Est. Return

Bank of New York Mellon's AARD Position: Q2 2026 in Review

Bank of New York Mellon sold out of Aardvark Therapeutics (AARD) in Q2 2026, closing a stake of 29,320 shares — an estimated $111K sold.

Bank of New York Mellon first reported a position in AARD in Q3 2025 and held it in 3 quarters. The position peaked at $294K in Q4 2025. 27 funds tracked by Wall St. Rank hold AARD as of Q2 2026.

  • Bank of New York Mellon reported no remaining Aardvark Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Bank of New York Mellon sold 29,320 Aardvark Therapeutics shares in Q2 2026, an estimated $111K.
  • Bank of New York Mellon first reported a position in Aardvark Therapeutics in Q3 2025 and held it in 3 quarters.
  • Bank of New York Mellon's Aardvark Therapeutics position peaked at $294K in Q4 2025.
  • 27 funds tracked by Wall St. Rank held Aardvark Therapeutics as of Q2 2026.

Based on Bank of New York Mellon's 13F filing for Q2 2026, filed 6 Aug 2026.